Welcome to Multibagg AI
Log in to access personalized features
Bearish
5
Neutral
5
Bullish
4
Bearish
5
Neutral
17
Bullish
24
Bearish
0
Neutral
12
Bullish
20
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
17.20 | 26 Cr | 4.29 | 0.80 | 0.00 | 15.59 | 20.51 | 12.72 | ||
31.17 | 25 Cr | -20.30 | 2.85 | 0.00 | -13.06 | 39.56 | -5.20 | ||
9.00 | 25 Cr | 21.95 | 0.60 | 0.00 | 3.48 | 6.70 | 1.16 | ||
37.60 | 25 Cr | -163.48 | 0.00 | 0.00 | 18.25 | -230.92 | -328.57 | ||
79.75 | 24 Cr | 26.85 | 2.14 | 0.00 | 8.65 | 10.56 | 6.11 | ||
11.50 | 22 Cr | 6.57 | 0.72 | 0.00 | 2.67 | 6.38 | 0.70 | ||
25.60 | 22 Cr | 23.20 | 2.21 | 0.00 | 4.02 | 3.11 | 6.37 | ||
| Median: 7 Co. | — | 25.60 | 25 Cr | 6.57 | 0.80 | 0.00 | 4.02 | 6.70 | 1.16 |
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Pharmaceuticals & Biotechnology
Pharmaceuticals
25 Cr
Low Risk
-163.5
31.7
—
—
37.60
6.75
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Rekvina Labs Ltd (VINRKLB) is currently trading at 40.66 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Rekvina Labs Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Rekvina Labs Ltd has traded between a low of ₹6.75 and a high of ₹37.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Rekvina Labs Ltd has a market capitalization of approximately 24.51. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Rekvina Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -163.48 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 24.51 Cr, Rekvina Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Rekvina Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Rekvina Labs Ltd is -163.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Voting Results
Rekvina Laboratories disclosed voting results and the consolidated Scrutinizer Report for the EGM held on 10-Apr-2026 (record date 03-Apr-2026): six resolutions passed including increase in authorised share capital; promoters polled 1,745,490 votes (70.11%) all in favour.
Voting Results
Rekvina Laboratories disclosed voting results and the scrutinizer's report for the EGM held 10-Apr-2026; six resolutions were passed, including increase in authorised share capital; promoters cast 1,745,490 e-votes (70.11%) all in favour.
Capital & Preferential Issue
Rekvina Laboratories held an EGM on 10 Apr 2026 to approve increase in authorised share capital, amend MOA/AOA, approve s.186 exceedance, related‑party transactions and preferential equity issues (cash & non‑cash).
